Artelo Biosciences (ARTL) vs Genprex (GNPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genprex is the larger company by market cap ($2.3 million vs $1.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | GNPX |
|---|---|---|
| Share price | $3.37 | $2.75 |
| Market cap | $1.85M | $2.25M |
| 1-day change | -1.17% | +4.96% |
| EPS (TTM) | $-136.26 | $-9.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $1,210.00 |
| 52-week low | $3.33 | $2.53 |
| Distance from 52-week high | -98.12% | -99.77% |
| Average volume | 480.92K | 247.06K |
| Shares outstanding | 547.77K | 819.71K |
| Employees | 7 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Genprex
GNPX stock →Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
ARTL vs GNPX FAQ
Which is bigger, Artelo Biosciences or Genprex?
Genprex (GNPX) is larger, with a market capitalization of $2.25M compared with $1.85M for Artelo Biosciences (ARTL).
Are Artelo Biosciences and Genprex in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.